Market Currents
Salix Pharmaceuticals (SLXP -4.8%) slides after Auriga downgrades the stock to Hold from Buy and...
-
Tuesday, April 10, 2012, 11:20 AM ETSalix Pharmaceuticals (SLXP -4.8%) slides after Auriga downgrades the stock to Hold from Buy and lowers its price target to $51 from $54. The firm says SLXP shares appear to have already priced in upside from the potential approval of developmental drugs Relistor and Crofelemer. Auriga had upgraded shares to Buy only six weeks ago.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
